| Literature DB >> 36175786 |
Yasemin Ekmekyapar Fırat1, Türkan Turgay2, Selver Seval Soğan3, Pınar Günel Karadeniz4.
Abstract
BACKGROUND: Parkinson's disease (PD) is a neurodegenerative disease with motor and non-motor symptoms affecting the quality of life. This study aimed to investigate the effects of the Lee Silverman Voice Therapy (LSVT)-BIG rehabilitation program via telerehabilitation on quality of life, motor and non-motor symptoms in people with Parkinson's disease (PwPD), and their correlation with each other.Entities:
Keywords: LSVT-BIG; Parkinson’s disease; Quality of life; Telerehabilitation
Year: 2022 PMID: 36175786 PMCID: PMC9521849 DOI: 10.1007/s13760-022-02104-x
Source DB: PubMed Journal: Acta Neurol Belg ISSN: 0300-9009 Impact factor: 2.471
Patient characteristics
| Gender | |
| Male | 9 (60) |
| Female | 6 (40 |
| Age (Mean ± SD) | 63.13 ± 9.89 |
| Height (Mean ± SD) | 165.13 ± 9.98 |
| Weight (Mean ± SD) | 77.07 ± 10.23 |
| BMI (Mean ± SD) | 28.44 ± 4.24 |
| Marital status | |
| Married | 14 (93.3) |
| Single | 1 (6.7) |
Educational status Illiterate Literate Primary school Middle school High School University and higher | 2 (13.3) 1 (6.7) 4 (26.7) 2 (13.3) 3 (20.0) 3 (20.0) |
Parkinson’s treatment Levodopa (mg/day) 250 300 375 500 625 700 1725 Dopamine agonists MAO-B inhibitors Amantadine | 11 (73.3) 1 (6.6) 1 (6.6) 5 (33.3) 1 (6.6) 1 (6.6) 1 (6.6) 1 (6.6) 8 (53.3) 13 (86.6) 3 (20) |
| Comorbid disease | |
| Yes | 5 (33.3) |
| No | 10 (67.7) |
| Other drugs used | |
| Yes | 12 (80.0) |
| No | 3 (20.0) |
Years since diagnosis Less than 1 year 1–3 years 4–5 years 6–10 years 16–20 years | 7 (46.7) 3 (20.0) 1 (6.7) 3 (20.0) 1 (6.7) |
Hoehn–Yahr stage 1 2 3 | 7 (46.7) 5 (33.3) 3 (20.0) |
n number, Mean arithmetic mean, SD standard deviation
PDQ-39 and MDS-UPDRS assessment comparison before and after exercise
| Before | After | ||
|---|---|---|---|
| PDQ-39-Mobility | 77.5 (10.0–82.5) | 7.5 (0.0–25.0) | 0.002a |
| PDQ-39-Activities of daily living | 29.2 (8.3–79.8) | 8.3 (0.0–33.3) | 0.004a |
| PDQ-39-Emotional well-being | 29.2 (16.7–70.83) | 16.7 (0.0–25.0) | 0.002a |
| PDQ-39-Stigma | 18.8 (0.0–25.0) | 0.0 (0.0–12.5) | 0.019a |
| PDQ-39-Social support | 0.0 (0.0–33.3) | 0.0 (0.0–8.3) | 0.058a |
| PDQ-39-Cognition | 37.5 (18.8–56.3) | 25.0 (12.5–25.0) | 0.007a |
| PDQ-39-Communication | 0.0 (0.0–25.0) | 0.0 (0.0–8.3) | 0.017a |
| PDQ-39-Bodily discomfort | 50.0 (33.3–83.3) | 16.7 (8.3–50.0) | 0.001a |
| PDQ-39-Summary index | 38.9 (12.2–47.4) | 11.4 (5.7–23.4) | 0.001a |
| MDS-UPDRS part I | 14.73 ± 10.98 | 5.40 ± 4.39 | < 0.001b |
| MDS-UPDRS part II | 10.00 (9.00–20.00) | 4.00 (1.00–9.00) | 0.001a |
| MDS-UPDRS part III | 27.47 ± 11.36 | 7.53 ± 5.04 | < 0.00b |
Avg arithmetic mean, SD standard deviation, Q 1. quartile, Q 3. quartile
aWilcoxon signed-rank test
bPaired samples t test
Correlation between PDQ-39 subgroups and MDS-UPDRS parts
| PDQ-39 | MDS-UPDRS | |||||
|---|---|---|---|---|---|---|
| Part I | Part II | Part III | ||||
| Before | After | Before | After | Before | After | |
| Mobility | ||||||
0.576 0.025 | 0.894 < 0.001 | 0.742 0.002 | 0.777 0.001 | 0.471 0.077 | 0.791 < 0.001 | |
| Activities of daily living | ||||||
0.570 0.026 | 0.581 0.023 | 0.815 < 0.001 | 0.735 0.002 | 0.458 0.086 | 0.445 0.097 | |
| Emotional well-being | ||||||
0.596 0.019 | 0.519 0.047 | 0.384 0.158 | 0.275 0.321 | 0.281 0.310 | 0.487 0.065 | |
| Stigma | ||||||
0.224 0.422 | 0.167 0.552 | 0.316 0.252 | 0.272 0.326 | 0.051 0.858 | -0.141 0.617 | |
| Social support | ||||||
0.452 0.091 | 0.396 0.144 | 0.444 0.097 | 0.586 0.022 | 0.710 0.003 | 0.357 0.192 | |
| Cognition | ||||||
0.803 < 0.001 | 0.705 0.003 | 0.388 0.153 | 0.471 0.076 | 0.081 0.775 | 0.591 0.020 | |
| Communication | ||||||
0.723 0.002 | 0.603 0.017 | 0.755 0.001 | 0.757 0.001 | 0.570 0.026 | 0.446 0.096 | |
| Bodily discomfort | ||||||
0.532 0.041 | 0.872 < 0.001 | 0.639 0.010 | 0.668 0.007 | 0.158 0.573 | 0.743 0.001 | |
| Summary index | ||||||
0.773 0.001 | 0.891 < 0.001 | 0.824 < 0.001 | 0.859 < 0.001 | 0.461 0.084 | 0.737 0.002 | |